Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Toshihiro Yokoi"'
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s)
Externí odkaz:
https://doaj.org/article/a47ce881037545fd9257a49e41ccbe12
Autor:
Kunle Odunsi, Takaaki Oba, Hans Minderman, Kenichi Makino, Ryutaro Kajihara, Toshihiro Yokoi, Ryoko Araki, Masumi Abe, Alfred E Chang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty t
Externí odkaz:
https://doaj.org/article/b0b53910545d499abfe3d46f4a5b5925
Publikováno v:
Interdisciplinary Neurosurgery, Vol 6, Iss C, Pp 8-12 (2016)
Ventral midbrain cavernous malformations are rare, and annual bleeding rate is higher than supratentorial lesions. Rebleeding rate is also high if surgical resection is incomplete. The ventral midbrain is deeply located and surrounded by many perfora
Externí odkaz:
https://doaj.org/article/804ae6d8a65743839321db5b7d750d12
Autor:
Toshihiro Yokoi, Konomi Mochizuki, Takayuki Nakamura, Satoshi Nishiyama, Kensuke Takahashi, Takeshi Osaka
Publikováno v:
NTT Technical Review. 21:18-23
Supplementary Information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069ffed4ddf2e9a0a7ebad759d1224c7
https://doi.org/10.1158/0008-5472.22430686.v1
https://doi.org/10.1158/0008-5472.22430686.v1
Neoadjuvant immunotherapy, given before surgical resection, is a promising approach to develop systemic antitumor immunity for the treatment of high-risk resectable disease. Here, using syngeneic and orthotopic mouse models of triple-negative breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae17628f6eec4f91b124e1c9ab417c3d
https://doi.org/10.1158/0008-5472.c.6513685.v1
https://doi.org/10.1158/0008-5472.c.6513685.v1
Publikováno v:
Cancer Res
Neoadjuvant immunotherapy, given before surgical resection, is a promising approach to develop systemic antitumor immunity for the treatment of high-risk resectable disease. Here, using syngeneic and orthotopic mouse models of triple-negative breast
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is criti
Publikováno v:
J Immunol
Intralesional therapy is a promising approach for remodeling the immunosuppressive tumor microenvironment while minimizing systemic toxicities. A combinatorial in situ immunomodulation (ISIM) regimen with intratumoral administration of Fms-like tyros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::944e866cabfba039ba15de56ae5f3dd7
https://europepmc.org/articles/PMC8387427/
https://europepmc.org/articles/PMC8387427/
Autor:
Fumito Ito, Kenichi Makino, Takaaki Oba, Ryutaro Kajihara, Alfred E. Chang, Kunle Odunsi, Hans Minderman, Toshihiro Yokoi, Masumi Abe, Ryoko Araki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to